Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

fluorine F 18 DASA-23

A radiotracer composed of DASA-23, a pyruvate kinase isoform M2 (PKM2) ligand, conjugated to the radioisotope fluorine F 18, with potential use for imaging of PKM2-expressing tumor cells upon positron emission tomography (PET). Upon administration of fluorine F 18 DASA-23, the DASA-23 moiety selectively targets and is taken up by tumor cells that express PKM2. Upon binding to PKM2 and following PET, PKM2-expressing tumor cells can be visualized and the metabolic activity of the tumor cells can be assessed through the quantitation of PKM2 expression levels. PKM2, an enzyme that plays a key role in the glycolytic reprogramming, metabolic activity and rapid proliferation of tumor cells, is selectively overexpressed in various tumor cell types. Tumor uptake of fluorine F 18 DASA-23 is positively correlated with PKM2 expression.
Synonym:18F-DASA-23
F18-labeled PKM2 inhibitor DASA-23
F18-labeled pyruvate kinase M2 inhibitor DASA-23
Chemical structure:1-((2-fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine
Search NCI's Drug Dictionary